CALA Calithera Biosciences Inc

Price (delayed)

$2.16

Market cap

$159.94M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.21

Enterprise value

$61.03M

Sector: Healthcare
Industry: Biotechnology

Highlights

Calithera Biosciences's debt has plunged by 57% YoY and by 44% from the previous quarter
CALA's EPS is up by 30% year-on-year and by 8% since the previous quarter
The quick ratio has grown by 19% from the previous quarter but it has contracted by 13% YoY
Calithera Biosciences's equity has decreased by 26% YoY and by 8% from the previous quarter

Key stats

What are the main financial stats of CALA
Market
Shares outstanding
74.05M
Market cap
$159.94M
Enterprise value
$61.03M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.68
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$86.09M
EBITDA
-$84.26M
Free cash flow
-$79.35M
Per share
EPS
-$1.21
Free cash flow per share
-$1.1
Book value per share
$1.28
Revenue per share
$0
TBVPS
$1.53
Balance sheet
Total assets
$110.66M
Total liabilities
$16.5M
Debt
$2.71M
Equity
$94.16M
Working capital
$92.72M
Liquidity
Debt to equity
0.03
Current ratio
7.72
Quick ratio
7.55
Net debt/EBITDA
1.17
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-62.7%
Return on equity
-74.5%
Return on invested capital
-636.6%
Return on capital employed
-88.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CALA stock price

How has the Calithera Biosciences stock price performed over time
Intraday
6.4%
1 week
10.2%
1 month
0.47%
1 year
-67.66%
YTD
-56.01%
QTD
-10.74%

Financial performance

How have Calithera Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$87.08M
Net income
-$86.09M
Gross margin
N/A
Net margin
N/A
Calithera Biosciences's operating income has increased by 7% YoY and by 4.7% QoQ
The net income is up by 5% year-on-year and by 4.5% since the previous quarter

Growth

What is Calithera Biosciences's growth rate over time

Valuation

What is Calithera Biosciences stock price valuation
P/E
N/A
P/B
1.68
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CALA's EPS is up by 30% year-on-year and by 8% since the previous quarter
The P/B is 33% less than the last 4 quarters average of 2.5 and 12% less than the 5-year quarterly average of 1.9
Calithera Biosciences's equity has decreased by 26% YoY and by 8% from the previous quarter

Efficiency

How efficient is Calithera Biosciences business performance
CALA's ROIC has shrunk by 174% QoQ
CALA's ROA is down by 9% year-on-year and by 2.3% since the previous quarter
CALA's return on equity is down by 9% year-on-year and by 2.5% since the previous quarter

Dividends

What is CALA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CALA.

Financial health

How did Calithera Biosciences financials performed over time
The total liabilities has declined by 29% since the previous quarter and by 25% year-on-year
Calithera Biosciences's total assets has decreased by 26% YoY and by 12% from the previous quarter
Calithera Biosciences's debt is 97% less than its equity
Calithera Biosciences's debt has plunged by 57% YoY and by 44% from the previous quarter
The debt to equity has declined by 40% since the previous quarter and by 40% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.